Promising New Inhibitors of Tyrosyl-DNA Phosphodiesterase I (Tdp 1) Combining 4-Arylcoumarin and Monoterpenoid Moieties as Components of Complex Antitumor Therapy

Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an important DNA repair enzyme in humans, and a current and promising inhibition target for the development of new chemosensitizing agents due to its ability to remove DNA damage caused by topoisomerase 1 (Top1) poisons such as topotecan and irinotecan. Herein, we report our work on the synthesis and characterization of new Tdp1 inhibitors that combine the arylcoumarin (neoflavonoid) and monoterpenoid moieties. Our results showed that they are potent Tdp1 inhibitors with IC50 values in the submicromolar range. In vivo experiments with mice revealed that compound 3ba (IC50 0.62 µM) induced a significant increase in the antitumor effect of topotecan on the Krebs-2 ascites tumor model. Our results further strengthen the argument that Tdp1 is a druggable target with the potential to be developed into a clinically-potent adjunct therapy in conjunction with Top1 poisons.

[1]  I. Qureshi,et al.  Synthesis and biological evaluation of morpholines linked coumarin–triazole hybrids as anticancer agents , 2019, Chemical biology & drug design.

[2]  C. Bailly.  Irinotecan: 25 years of cancer treatment. , 2019, Pharmacological research.

[3]  O. Lavrik,et al.  New Hydrazinothiazole Derivatives of Usnic Acid as Potent Tdp1 Inhibitors , 2019, Molecules.

[4]  O. Lavrik,et al.  Dehydroabietylamine Ureas and Thioureas as Tyrosyl-DNA Phosphodiesterase 1 Inhibitors That Enhance the Antitumor Effect of Temozolomide on Glioblastoma Cells. , 2019, Journal of Natural Products.

[5]  Zhi Xu,et al.  Coumarin-containing hybrids and their anticancer activities. , 2019, European journal of medicinal chemistry.

[6]  W. Reinhold,et al.  Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents , 2019, bioRxiv.

[7]  O. Lavrik,et al.  The Development of Tyrosyl-DNA Phosphodiesterase 1 Inhibitors. Combination of Monoterpene and Adamantine Moieties via Amide or Thioamide Bridges , 2019, Applied Sciences.

[8]  O. Lavrik,et al.  Dual DNA topoisomerase 1 and tyrosyl‐DNA phosphodiesterase 1 inhibition for improved anticancer activity , 2019, Medicinal research reviews.

[9]  J. Singh,et al.  Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids. , 2019, Bioorganic & medicinal chemistry.

[10]  Y. Pommier,et al.  Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening. , 2019, Nucleic acids research.

[11]  T. Bucciarelli,et al.  UHPLC-UV/Vis Quantitative Analysis of Hydroxylated and O-prenylated Coumarins in Pomegranate Seed Extracts , 2019, Molecules.

[12]  O. Lavrik,et al.  Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma , 2019, Bulletin of Experimental Biology and Medicine.

[13]  B. Patel,et al.  Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update. , 2019, European journal of medicinal chemistry.

[14]  O. Lavrik,et al.  Novel Inhibitors of DNA Repair Enzyme TDP1 Combining Monoterpenoid and Adamantane Fragments. , 2019, Anti-cancer agents in medicinal chemistry.

[15]  Seegehalli M. Anil,et al.  Synthesis of new coumarin tethered isoxazolines as potential anticancer agents. , 2018, Bioorganic & medicinal chemistry letters.

[16]  Zhi Xu,et al.  Design, Synthesis, and Evaluation of Tetraethylene Glycol Tethered Isatin-Coumarin Hybrids as Novel Anticancer Agents , 2018, Journal of Heterocyclic Chemistry.

[17]  S. B. Jonnalagadda,et al.  Synthesis, computational studies and antiproliferative activities of coumarin-tagged 1,3,4-oxadiazole conjugates against MDA-MB-231 and MCF-7 human breast cancer cells. , 2018, Bioorganic & medicinal chemistry.

[18]  J. Reynisson,et al.  The Development of a Weighted Index to Optimise Compound Libraries for High Throughput Screening , 2018, Molecular informatics.

[19]  O. Lavrik,et al.  A Novel Class of Tyrosyl-DNA Phosphodiesterase 1 Inhibitors That Contains the Octahydro-2H-chromen-4-ol Scaffold , 2018, Molecules.

[20]  Yunxiang Liang,et al.  A polysaccharide from Antrodia cinnamomea mycelia exerts antitumor activity through blocking of TOP1/TDP1-mediated DNA repair pathway. , 2018, International journal of biological macromolecules.

[21]  Jong-Wha Jung,et al.  Recent Advances in Synthesis of 4-Arylcoumarins , 2018, Molecules.

[22]  S. Awale,et al.  Chemical Constituents of Thai Citrus hystrix and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line. , 2018, Journal of natural products.

[23]  B. Chelobanov,et al.  Synthesis and evaluation of aryliden- and hetarylidenfuranone derivatives of usnic acid as highly potent Tdp1 inhibitors. , 2018, Bioorganic & medicinal chemistry.

[24]  K. Majidzadeh-A,et al.  Synthesis and biological evaluation of new coumarins bearing 2,4-diaminothiazole-5-carbonyl moiety. , 2018, European journal of medicinal chemistry.

[25]  Aliya Ibrar,et al.  Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery. , 2018, Bioorganic & medicinal chemistry.

[26]  M. Mounier,et al.  Design, synthesis and molecular modeling of new 4-phenylcoumarin derivatives as tubulin polymerization inhibitors targeting MCF-7 breast cancer cells. , 2018, Bioorganic & medicinal chemistry.

[27]  I. I. Popadyuk,et al.  Novel Semisynthetic Derivatives of Bile Acids as Effective Tyrosyl-DNA Phosphodiesterase 1 Inhibitors , 2018, Molecules.

[28]  O. Lavrik,et al.  Aminoadamantanes containing monoterpene-derived fragments as potent tyrosyl-DNA phosphodiesterase 1 inhibitors. , 2018, Bioorganic chemistry.

[29]  F. Leonetti,et al.  Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds , 2018, Molecules.

[30]  O. Lavrik,et al.  Novel group of tyrosyl-DNA-phosphodiesterase 1 inhibitors based on disaccharide nucleosides as drug prototypes for anti-cancer therapy , 2018, Journal of enzyme inhibition and medicinal chemistry.

[31]  L. Povirk,et al.  Tyrosyl–DNA phosphodiesterases: rescuing the genome from the risks of relaxation , 2017, Nucleic acids research.

[32]  S. Yachida,et al.  Current status of poly(ADP-ribose) polymerase inhibitors and future directions , 2017, OncoTargets and therapy.

[33]  S. D. Guggilapu,et al.  Umbelliferone–oxindole hybrids as novel apoptosis inducing agents , 2017 .

[34]  T. Pfeifer,et al.  Achyrodimer F, a tyrosyl-DNA phosphodiesterase I inhibitor from an Australian fungus of the family Cortinariaceae. , 2017, Bioorganic & medicinal chemistry letters.

[35]  V. Zarubaev,et al.  Anti-influenza activity of monoterpene-containing substituted coumarins. , 2017, Bioorganic & medicinal chemistry letters.

[36]  T. Yoshimura,et al.  Evaluation of synthesized coumarin derivatives on aromatase inhibitory activity. , 2017, Bioorganic & medicinal chemistry letters.

[37]  M. Itoigawa,et al.  Cancer chemopreventive constituents from Melicope lunu-ankenda , 2017 .

[38]  Petra Schneider,et al.  Privileged Structures Revisited , 2017, Angewandte Chemie.

[39]  F. Belluti,et al.  Coumarin derivatives as potential antitumor agents: Growth inhibition, apoptosis induction and multidrug resistance reverting activity. , 2017, European journal of medicinal chemistry.

[40]  V. Svedas,et al.  Tyrosyl-DNA Phosphodiesterase 1 Inhibitors: Usnic Acid Enamines Enhance the Cytotoxic Effect of Camptothecin. , 2016, Journal of natural products.

[41]  O. Lavrik,et al.  New inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 7-hydroxycoumarin and monoterpenoid moieties. , 2016, Bioorganic & medicinal chemistry.

[42]  O. Lavrik,et al.  Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential. , 2016, Bioorganic & medicinal chemistry.

[43]  N. Jain,et al.  Synthesis and antiproliferative activity of 6,7-aryl/hetaryl coumarins , 2016, Russian Journal of General Chemistry.

[44]  Haitao Liu,et al.  Design, Synthesis, and In Vitro Evaluation of Novel 3, 7‐Disubstituted Coumarin Derivatives as Potent Anticancer Agents , 2015, Chemical biology & drug design.

[45]  M. D. Hill,et al.  Applications of Fluorine in Medicinal Chemistry. , 2015, Journal of medicinal chemistry.

[46]  R. Schmid,et al.  The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl‐DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis , 2015, Arthritis & rheumatology.

[47]  O. Lavrik,et al.  Synthesis and biological evaluation of novel tyrosyl-DNA phosphodiesterase 1 inhibitors with a benzopentathiepine moiety. , 2015, Bioorganic & medicinal chemistry.

[48]  Steven J. M. Jones,et al.  Identification of a Putative Tdp1 Inhibitor (CD00509) by in Vitro and Cell-Based Assays , 2014, Journal of biomolecular screening.

[49]  S. Ward,et al.  TDP1/TOP1 Ratio as a Promising Indicator for the Response of Small Cell Lung Cancer to Topotecan , 2014, Journal of cancer science & therapy.

[50]  M. O'sullivan,et al.  TDP1 and PARP1 Deficiency Are Cytotoxic to Rhabdomyosarcoma Cells , 2013, Molecular Cancer Research.

[51]  Feng Zhu,et al.  Wine Compounds as a Source for HTS Screening Collections. A Feasibility Study , 2012, Molecular informatics.

[52]  J. Hashimoto,et al.  Tyrosyl-DNA phosphodiesterase 1 inhibitor from an anamorphic fungus. , 2012, Journal of natural products.

[53]  Y. Pommier,et al.  Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Repairs DNA Damage Induced by Topoisomerases I and II and Base Alkylation in Vertebrate Cells* , 2012, The Journal of Biological Chemistry.

[54]  Y. Pommier,et al.  Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors , 2011, Expert opinion on therapeutic patents.

[55]  S. Genovese,et al.  Auraptene: a natural biologically active compound with multiple targets. , 2011, Current drug targets.

[56]  C. Shayo,et al.  Coumarins: old compounds with novel promising therapeutic perspectives. , 2010, Current medicinal chemistry.

[57]  Iwona E. Weidlich,et al.  4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors. , 2009, Journal of medicinal chemistry.

[58]  Thomas Stützle,et al.  Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..

[59]  Jóhannes Reynisson,et al.  Benchmarking the reliability of QikProp. Correlation between experimental and predicted values , 2008 .

[60]  K. Caldecott,et al.  TDP1 facilitates chromosomal single‐strand break repair in neurons and is neuroprotective in vivo , 2007, The EMBO journal.

[61]  M. Bjornsti,et al.  Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison. , 2007, Journal of molecular biology.

[62]  Yves Pommier,et al.  Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1 , 2007, Nucleic acids research.

[63]  M. Brock,et al.  Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. , 2007, Lung cancer.

[64]  P. Houghton,et al.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Yves Pommier,et al.  Inhibition of Human Tyrosyl-DNA Phosphodiesterase by Aminoglycoside Antibiotics and Ribosome Inhibitors , 2006, Molecular Pharmacology.

[66]  Marcel L Verdonk,et al.  General and targeted statistical potentials for protein–ligand interactions , 2005, Proteins.

[67]  J. Champoux,et al.  SCAN1 mutant Tdp1 accumulates the enzyme–DNA intermediate and causes camptothecin hypersensitivity , 2005, The EMBO journal.

[68]  Morten O. Christensen,et al.  TDP1 Overexpression in Human Cells Counteracts DNA Damage Mediated by Topoisomerases I and II* , 2004, Journal of Biological Chemistry.

[69]  Haruki Nakamura,et al.  Announcing the worldwide Protein Data Bank , 2003, Nature Structural Biology.

[70]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[71]  J. Champoux,et al.  Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. , 2002, Journal of molecular biology.

[72]  Huili Chen,et al.  Effects of phosphatidylinositol 4,5-bisphosphate and neomycin on phospholipase D: Kinetic studies , 1999, Molecular and Cellular Biochemistry.

[73]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[74]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[75]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[76]  Isabel Leung,et al.  Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topoteсan on in vivo tumor models. , 2019, European journal of medicinal chemistry.

[77]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..